WallStSmart

CONMED Corporation (CNMD)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 341% more annual revenue ($6.07B vs $1.37B). EW leads profitability with a 17.7% profit margin vs 3.4%. CNMD appears more attractively valued with a PEG of 1.84. EW earns a higher WallStSmart Score of 55/100 (C).

CNMD

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 4.3
Piotroski: 1/9

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CNMDSignificantly Overvalued (-312.2%)

Margin of Safety

-312.2%

Fair Value

$10.27

Current Price

$37.08

$26.81 premium

UndervaluedFair: $10.27Overvalued
EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CNMD1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

Areas to Watch

CNMD4 concerns · Avg: 3.3/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Market CapQuality
$1.13B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.7%3/10

ROE of 4.7% — below average capital efficiency

Profit MarginProfitability
3.4%3/10

3.4% margin — thin

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : CNMD

The strongest argument for CNMD centers on Price/Book.

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bear Case : CNMD

The primary concerns for CNMD are PEG Ratio, Market Cap, Return on Equity. Thin 3.4% margins leave little buffer for downturns.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Key Dynamics to Monitor

CNMD profiles as a value stock while EW is a mature play — different risk/reward profiles.

EW carries more volatility with a beta of 0.93 — expect wider price swings.

EW is growing revenue faster at 13.3% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 49/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CONMED Corporation

HEALTHCARE · MEDICAL DEVICES · USA

CONMED Corporation, a medical technology company, develops, manufactures and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company is headquartered in Largo, Florida.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?